BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Tyligand Bioscience Doses First Patient in Phase 1/2 Trial for Innovative KRAS G12D Cancer Therapy

Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the fir...

May 27, 2024 | News

Laekna Receives FDA Approval for Phase III Trial of Innovative mCRPC Treatment

Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food an...

May 24, 2024 | News

Ractigen Therapeutics' saRNA Drug RAG-01 Receives Fast Track Designation from FDA

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, proudly announces that its flagship program, RAG-01, has been g...

May 22, 2024 | News

RemeGen Announces Completion of Patient Enrollment for Two Phase III Clinical Trials of Telitacicept in China

RemeGen Co. a commercial-stage biotechnology company, recently announced significant progress of Telitacicept (RC18), that two Phase III clinical tria...

May 22, 2024 | News

Innovent Biologics' New Drug for Thyroid Eye Disease Granted Priority Review in China

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatm...

May 21, 2024 | News

Ractigen Therapeutics Receives IND Approval for Phase 1 ALS Clinical Trials in China

Ractigen Therapeutics, a clinical-stage pharmaceutical company committed to developing pioneering therapies, announces that the Center for Drug ...

May 16, 2024 | News

EFECON® Becomes First Approved Therapy for IgAN in China, Offering Hope to Millions with Improved Patient Care and Disease Management

Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines ...

May 15, 2024 | News

Eisai's Antiepileptic Drug Fycompa® Gains Approval in China for Additional Indication

Eisai Co., Ltd. announced that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa&...

May 14, 2024 | News

Mabwell Advances Clinical Study of Nectin-4-Targeting ADC for Triple-Negative Breast Cancer

Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targ...

May 14, 2024 | News

Brii Biosciences Secures Breakthrough Therapy Designations for Two HBV Treatments from NMPA

Brii Biosciences Limited a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need,...

May 14, 2024 | News

WestGene Achieves FDA Approval for World's First EB Virus-Related mRNA Cancer Vaccine, WGc-043

WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, ...

May 13, 2024 | News

NeuShen Therapeutics Begins Phase I Trial of NS-136, a Potential Breakthrough in Schizophrenia Treatment

NeuShen Therapeutics , a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today a...

May 10, 2024 | News

Ribobay Pharma Partners with Cytiva to Launch Pioneering Oligonucleotide Manufacturing Platform in China

Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO) and a spin-off company of Genera...

May 09, 2024 | News

Biocytogen Partners with BioCopy for TCR-Mimic Antibody Development

Biocytogen Pharmaceuticals, a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antib...

May 07, 2024 | News

Stay Connected